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Background
The issue of acquired resistance to breast cancer regimes
such as tamoxifen continues to negatively affect clinical
outcomes. While many mechanisms of resistance have
been discovered [1,2], there is evidence now of acquired
resistance through adaptation of the oestrogen receptor
itself leading to tumour progression [3]. A thorough
understanding of the processes involved in the receptor's
adaptation remains unclear. This study gives evidence of
the gene signalling which shed light on the mechanism of
adaptation in an LY2 endocrine resistant cell line oestro-
gen receptor knockdown model.
Methods
Real time PCR examines the gene expression profile of the
LY2 cells under various treatments including oestrogen,
tamoxifen and a mixture of both.
Results
It was found that the normal oestrogen receptor target
genes PS2 and GREB1 display reduced expression without
the presence of the receptor. However EGR3 signals exces-
sively despite having the receptor stably knockdown.
Conclusions
As a result these data provides evidence that EGR3 is
involved in the adaptation of the oestrogen receptor and
that global signalling of common target genes does not
occur when the receptor adapts. Hence it demonstrates an
initial clue of the process of adaptation in resistant
tumours that have changed their receptor status.
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